Recent Press Releases

Actavis Net Revenue Increases 34% to $2.67 Billion in Second Quarter 2014; Non-GAAP EPS Increases 70% to $3.42

Actavis Net Revenue Increases 34% to $2.67 Billion in Second Quarter 2014; Non-GAAP EPS Increases 70% to $3.42 - Second Quarter 2014 GAAP Earnings Per Diluted Share of $0.28 - - 82% Increase in...

Type 2 diabetes: Jentadueto® (linagliptin and metformin hydrochloride) tablets label updated to include new data on blood glucose reductions in treatment-naive adults with high baseline A1C

- Combination of linagliptin and metformin significantly reduced blood glucose levels compared with linagliptin alone

RIDGEFIELD, Conn.

Amgen Announces Phase 3 ASPIRE Trial Of Kyprolis® In Patients With Relapsed Multiple Myeloma Met Primary Endpoint

Kyprolis Helped Patients Live 8.7 Months Longer Without Their Disease Worsening

THOUSAND OAKS, Calif. and

Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit

Desperate Allergan Attempt to Interfere with the Special Meeting LAVAL, Quebec and NEW YORK, Aug. 1, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) and Pershing...

Allergan Files Lawsuit in Federal Court against Valeant and Pershing Square for Violations of Federal Securities Laws

Complaint Alleges Pershing Square and Valeant Circumvented Insider Trading Laws and Violated SEC Rule 14e-3 Allergan Believes Pershing Square and Valeant Have Failed to Disclose Material...

Kyprolis Helped Patients Live 8.7 Months Longer Without Their Disease Worsening Results to Form Basis of Regulatory Filings Beginning in 1H 2015

Kyprolis Helped Patients Live 8.7 Months Longer Without Their Disease Worsening Results to Form Basis of Regulatory Filings Beginning in 1H 2015 THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif.,...

FDA approves Jardiance® (empagliflozin) tablets for adults with type 2 diabetes

Third product from the BI-Lilly Diabetes alliance to be approved by FDA

RIDGEFIELD, Conn., and INDIANAPO

European Commission Grants Orphan Drug Designation to Soliris® (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG)

European Commission Grants Orphan Drug Designation to Soliris® (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG) CHESHIRE, Conn., Aug 01, 2014 (BUSINESS WIRE) -- Alexion...

GSK and Genmab announce positive interim result for phase III study of ofatumumab as maintenance therapy for relapsed CLL

GSK and Genmab announce positive interim result for phase III study of ofatumumab as maintenance therapy for relapsed CLL Issued: 31 July 2014, London UK GlaxoSmithKline plc (LSE/NYSE: GSK) and...

FDA approves Jardiance to treat type 2 diabetes

The U.S. Food and Drug Administration today approved Jardiance (empagliflozin) tablets as an addition to diet and exercise to improve glycemic control in adults with type 2 diabetes. Type 2...

Teva Reports Second Quarter 2014 Results

Teva Reports Second Quarter 2014 Results Revenues of $5.0 billion, up 2% compared to the second quarter of 2013. Non GAAP operating income of $1.4 billion, an increase of 8%. GAAP operating...

FDA approves Striverdi Respimat to treat chronic obstructive pulmonary disease

Today, the U.S. Food and Drug Administration approved Striverdi Respimat (olodaterol) inhalation spray to treat patients with chronic obstructive pulmonary disease (COPD), including chronic...

IQWIG DECISION (translated version)

IQWIG DECISION (translated version) Dossier evaluation A14-14 Version 1.0 Dimethyl fumarate - benefit assessment pursuant to § 35a SGB V 07/30/2014 Institute for Quality and Efficiency in Health...

Vertex Receives European Approval for KALYDECO(TM) (ivacaftor) in Eight Non-G551D Gating Mutations

Vertex Receives European Approval for KALYDECO(TM) (ivacaftor) in Eight Non-G551D Gating Mutations -In Europe, approximately 250 people ages 6 and older have one of 8 additional gating mutations-...

Managed Health Care Stocks Technical Review -- WellCare Health Plans, Aetna, Centene, WellPoint, and Molina Healthcare

Editor Note: For more information about this release, please scroll to bottom.

LONDON, July 30, 2014

InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada

PISCATAWAY, N.J., July 30, 2014 /PRNewswire/ -- InnoPharma, Inc.

Meda to acquire Rottapharm, creating a European specialty pharma leader

Meda to acquire Rottapharm, creating a European specialty pharma leader GÖTEBORG, Sweden--(Business Wire)--Regulatory News: Meda (STO:MEDAA): The combined entity will have enhanced scale, reach...

Dendreon Names W. Thomas Amick President and Chief Executive Officer

SEATTLE, Jul 30, 2014 (BUSINESS WIRE) -- Dendreon Corporation DNDN -0.71% today announced that its board of directors has appointed W. Thomas Amick as president and chief executive officer,...

New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015

(Washington, D.C.)—New high priced hepatitis C drugs will increase federal spending in Medicare Part D by a projected $2.9 to $5.8 billion next year, according to a new report by the actuarial...

COVINGTON ADVISES ASTRAZENECA ON STRATEGIC TRANSACTION WITH ALMIRALL IN RESPIRATORY DISEASE

COVINGTON ADVISES ASTRAZENECA ON STRATEGIC TRANSACTION WITH ALMIRALL IN RESPIRATORY DISEASE 7/30/2014 LONDON, 30 July, 2014 — Covington & Burling advised AstraZeneca on its agreement to...